Brokerages Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $12.68

enGene Holdings Inc. (NASDAQ:ENGN) has received a consensus recommendation of “Hold” from the fourteen ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $12.6818.

A number of brokerages have issued reports on ENGN. Citigroup downgraded enGene from a “market outperform” rating to a “market perform” rating in a research note on Friday, May 8th. Wells Fargo & Company restated an “equal weight” rating and issued a $2.00 price objective (down from $25.00) on shares of enGene in a research note on Friday, May 8th. Morgan Stanley downgraded enGene from an “overweight” rating to an “equal weight” rating in a research note on Friday, May 8th. HC Wainwright reduced their price objective on enGene from $25.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Leerink Partners downgraded enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price objective for the company. in a research note on Friday, May 8th.

enGene Trading Up 9.3%

NASDAQ ENGN opened at $1.77 on Tuesday. The firm has a market capitalization of $118.57 million, a P/E ratio of -0.79 and a beta of -0.29. The business has a fifty day simple moving average of $4.31 and a 200 day simple moving average of $7.19. enGene has a 12 month low of $1.40 and a 12 month high of $12.25. The company has a current ratio of 11.75, a quick ratio of 11.75 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Thursday, June 11th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.91. During the same period in the previous year, the business earned $0.51 earnings per share. On average, analysts predict that enGene will post -2.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Cresset Asset Management LLC bought a new position in enGene in the 2nd quarter valued at $36,000. Paloma Partners Management Co bought a new position in enGene in the 2nd quarter valued at $38,000. Raymond James Financial Inc. grew its stake in enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares during the period. Hudson Bay Capital Management LP bought a new position in enGene in the 3rd quarter valued at $76,000. Finally, PFS Partners LLC grew its stake in enGene by 22.2% in the 4th quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock valued at $99,000 after purchasing an additional 2,000 shares during the period. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.